BeyondSpring Inc. Reports Q1 2025 Results Amidst R&D Investments and Stock Volatility
BeyondSpring Inc. reported a GAAP loss of $0.08 per share in Q1 2025, but remains committed to advancing its pipeline of cancer therapies and innovative treatments.
2 minutes to read